METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta-1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.
1 . A method for evaluating renal status in a subject in acute renal failure, comprising:
performing an immunoassay configured to detect WAP four-disulfide core domain protein 2 by introducing a blood, serum or plasma sample obtained from the subject into an assay instrument which (i) contacts all or a portion of the sample with an antibody which specifically binds for detection WAP four-disulfide core domain protein 2, and (ii) generates an assay result indicative of binding of WAP four-disulfide core domain protein 2;
correlating the assay result(s) to the renal status of the subject generated by the assay instrument to the renal status of the subject by using the assay result to assign the subject to a predetermined subpopulation of individuals in acute renal failure having a known predisposition of recovery from acute renal failure, the assignment made by comparing the assay result or a value derived therefrom to a threshold selected in a population study to separate the population into a first subpopulation at higher predisposition for recovery from acute renal failure, and a second subpopulation at lower predisposition for recovery from acute renal failure relative to the first subpopulation; and
treating the subject based on the predetermined subpopulation of individuals to which the patient is assigned, wherein if the patient is in the second subpopulation, the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
2 . A method according to claim 1 , wherein said assay result comprises a measured concentration of WAP four-disulfide core domain protein 2.
3 . A method according to claim 2 , wherein the assay result is combined with one or more additional assay results using a function that converts the plurality of assay results into a single composite result.
4 . A method according to claim 1 , wherein the correlation step comprises assigning the patient to a predetermined subpopulation of individuals in acute renal failure having a known predisposition of recovery from acute renal failure within 72 hours of the time at which the body fluid sample is obtained.
5 . A method according to claim 1 , wherein said correlating step comprises assigning the patient to a predetermined subpopulation of individuals in acute renal failure having a known predisposition of recovery from acute renal failure within 48 hours of the time at which the body fluid sample is obtained.
6 . A method according to claim 1 , wherein said correlating step comprises assigning the patient to a predetermined subpopulation of individuals in acute renal failure having a known predisposition of recovery from acute renal failure within 24 hours of the time at which the body fluid sample is obtained.